clinical trials
The phased process (Phase 1, 2, 3) of testing a drug or vaccine for safety and efficacy before regulatory approval.
As defined in John Cochrane on the Pandemic
Where it comes up · 4
- John Cochrane on the Pandemic3 claims
- Michele Boldrin on Intellectual Property 05/18/20092 claims
- A Primer on Private Credit1 claim
- 106 - Humanity 2.01 claim
Most important claims · 7 of 7Search all claims for “clinical trials” →
- After the first several mRNA vaccines prove successful, regulators could treat the platform as reliable—as they already do with the annually changed flu vaccine that skips clinical trials on each variant—opening a future in which vaccines for new pandemics are developed in a weekend and rolled out the next week, putting a stop to one of humanity's great tragedies.John Cochrane on the Pandemic
- The standard pharmaceutical argument is that drug research has extreme fixed costs and very uncertain returns, so without patents no one would seek new drugs. This is both true and false, and evidence is limited because pharma is secretive. By the industry's own estimate, about 80% of the average cost of a new drug is clinical trials for FDA approval, not invention.Michele Boldrin on Intellectual Property 05/18/2009
- Because most people in standard vaccine trials are careful and few get exposed, requiring researchers to wait for tiny numbers of natural infections makes trials slow; allowing healthy young volunteers to deliberately expose themselves in challenge trials would have produced better data far more quickly, but the FDA refused on ethical grounds.John Cochrane on the Pandemic
- A structural flaw in drug testing is that new drugs are first tried only on people already going to die to look for a miracle, so a drug that is effective only earlier in the course of a disease—as hydroxychloroquine may have been—will appear useless or harmful and be wrongly dismissed.John Cochrane on the Pandemic
- The 'pharma needs patents because of high costs' argument uses clinical trials as a smokescreen. Clinical trials are a genuine public good imposed by regulation because of a principal-agent problem: firms have a temptation to shade safety results. Public money should therefore fund clinical trials on a competitive basis, for example by redirecting NIH funds, rather than basic research, which produces private goods embodied in labs.Michele Boldrin on Intellectual Property 05/18/2009
- Lenders should size their position well below enterprise value, because a loan equal to a business's value can become 100% loan-to-value if clinical trial spending burns the proceeds, so structure must stop the bleeding if things go badly.A Primer on Private Credit
- Because any therapeutic must demonstrate safety and effectiveness through clinical trials, patients being offered CRISPR options by their doctors for well-understood conditions is probably several years away at least.106 - Humanity 2.0